AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06235788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group ICEMS audio feedback with pause and expert video
Description: While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down, turning their attention to a 9-second expert-level demonstration video, and reflecting for 13 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
Study NCT06464094 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A
Description: Single group enrollment to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
Study NCT05396235 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; Intravenous (IV)
Study NCT05721976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With Love, Grandma (Con Cariño, Abuelita)
Description: Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period.
Study NCT06502509 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lemon tea
Description: Diluted lemon juice with the same pH as the commercial kombucha tea as placebo, which will be given to participants in opaque bottles for 8 weeks.
Study NCT03215849 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CRT-pacemaker device set to Routine Medical Therapy
Description: Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
Study NCT03215849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-pacemaker device set to Routine Medical Therapy + LVP
Description: Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
Study NCT03215849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-pacemaker device set to Routine Medical Therapy + BiVP
Description: Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
Study NCT05314101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
Study NCT05314101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
Study NCT04623515 — intervention group
Intervention type: OTHER
Intervention: REDCap Questionnaires
Description: Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
Study NCT05473013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Therapy for Eating Disorders
Description: Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
Study NCT05473013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy for Eating Disorders
Description: Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
Study NCT05473013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Monitoring On
Description: Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
Study NCT05473013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Reminder Messages
Description: Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
Study NCT05473013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JITAIs
Description: Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
Study NCT05625373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: The powder will be placed within the surgical wound prior to skin closure.
Study NCT05433740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proseal Laryngeal mask fixation
Description: fixation with Proseal Laryngeal mask adjustable ligament
Study NCT05688189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: different starting temperature setting of HFNC
Description: The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
Study NCT06489652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Oxine-RY_SW01 Cell Injection
Description: Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY_SW01 cells injection
Study NCT05671224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual aid
Description: Handout and video describing different types of induction of labor
Study NCT06489990 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combination intervention strategy of [Comorbidity-Co-causes-Joint-prevention]
Description: combination intervention strategy of \[Comorbidity-Co-causes-Joint-prevention\]
Study NCT06489990 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: routine health education and mental health knowledge
Description: routine health education and mental health knowledge
Study NCT05314101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
Study NCT06080854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks
Study NCT06080854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks
Study NCT06080854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
Study NCT06080854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions
Study NCT05076019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Study NCT05076019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Study NCT06495112 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Soft contact lens with lathe cut technique Lathe
Description: athe cut technique Lathe cutting involves shaping a solid block of lens material into the desired form using precision machinery. This method allows for customized lens designs but may result in a less smooth surface compared to cast molding. Cast molding, on the other hand, uses a liquid monomer that is cured in a mold to form the lens. This technique typically results in a smoother and more uniform lens surface.
Study NCT06495112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Soft contact lens with cast molding technique
Description: Participants in this arm would receive Cast molding soft contact lenses and would wear them according to the study protocol, also likely for a specified duration.The cast molding technique for soft contact lenses involves creating lenses by polymerizing a liquid monomer mixture within a mold that forms the desired lens shape. Here's a brief overview of the steps involved in the cast molding process
Study NCT06552156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Emulsifier
Description: Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
Study NCT06511739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SYHX1901
Description: SYHX1901 tablet
Study NCT06511739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: SYHX1901 tablet
Study NCT06511739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral tablet
Study NCT06395402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 dotatate therapy
Description: LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
Study NCT06395402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutetium Lu 177 dotatate therapy
Description: LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
Study NCT06313931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cognitive training via immersive virtual reality
Description: 20 minutes per session, twice a week for six weeks (totaling 12 sessions), using the cupboard task application.
Study NCT04937608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sperm analysis
Description: Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
Study NCT05606549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marital self disclosure
Description: Intervention time during hospitalization is the first day after chemotherapy, and intervene once per chemotherapy, a total of 4 times, 40-60 min each time. Interventions included verbal and written disclosure. The researcher will preside over the MSD process and introduce of MSD for gastric patients and their spouse，both patient and their spouse will receive a training or review on MSD skills, 5-10 minutes each time. Couples practice MSD skills through 4 revealing themes. Couples are encouraged to express their FCR, and when one partner disclosure, supporters should allow the speaker to fully express their feelings and respond positively to the speaker's message, showing empathy for them, and acknowledging their point of view.
Study NCT06456229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestle Isocal
Description: Nestle Isocal
Study NCT06456229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle Boost Optimum
Description: Nestle Boost Optimum
Study NCT06313931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training via paper and pencil
Description: 20 minutes per session, twice a week for six weeks (totaling 12 sessions), using cards.
Study NCT06313931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor stimulation
Description: motor stimulation for 12 sessions (20 minutes per session)
Study NCT06313931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor stimulation
Description: motor stimulation for 12 sessions (20 minutes per session)
Study NCT05127902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)
Description: Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG_max) for comparison with normalization signal processing program in Noraxon System.
Study NCT05379114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INVESTIGATIONAL DEVICE
Description: new medical device for the treatment of head lice infestation: Paranix ®
Study NCT05379114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device
Description: well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
Study NCT04863339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
Study NCT04863339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
Study NCT05682781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: Oral Nutritional Supplement
Study NCT05682781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Dietary Counseling
Study NCT05682781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Dietary Counseling
Study NCT05200520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite Self-Regulation Intervention
Description: The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
Study NCT04853979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRONE POSITION
Description: Any combination of prone or side position for 3 hours, 3 times a day for 3 days
Study NCT04853979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRONE POSITION
Description: Any combination of prone or side position for 3 hours, 3 times a day for 3 days
Study NCT05633121 — intervention group
Intervention type: PROCEDURE
Intervention: Rheopheresis
Description: Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
Study NCT05208294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulpiride 400 MG
Description: The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
Study NCT05208294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive an inactive placebo capsule.
Study NCT05208294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High expectation manipulation
Description: Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
Study NCT05208294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low expectation manipulation
Description: Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
Study NCT03285087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX 0.2 μg/kg/h.
Description: DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg bid
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg bid
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT06552156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Emulsifier
Description: Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT06076460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Total Enteral Feeding
Description: This group will receive enteral feeding volumes at a rate of 80 ml/kg/day starting within the first two hours after birth. Volumes will increased by 20 ml/kg/day till day 4 (total 140 ml/kg/d) and then 150ml/kg/day on day 5.
Study NCT06076460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Enteral Feeding
Description: This group will receive enteral feeding volumes at a rate of 20 ml/kg/day starting within the first two hours after birth and rest of the daily requirement as Total parenteral nutrition. Volumes will be increased by 20 ml/kg/day till day 3 and thereafter by 30 ml/kg/d till 150ml/kg/day on day 6.
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g qid
Study NCT06387550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: Warm up phase that include hip circles and shoulder rolls(1 sets of 5 reps), participants are trained on bicycle ergometer for 15 minutes on 2-3 times a week and its duration is increased according to patient tolerance, after that they will be pass through exercise phase that include squating, lunges and leg press (8-10 reps of 3 sets) after that cool down phase begin that include cat cow stretch and oblique stretch (5 reps of 1 set)
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1g bid
Study NCT05250050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g bid